R&D | January 02, 2025
Huadong Medicine and SynerK to jointly develop a novel siRNA drug SNK-2726
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Puri is an accomplished leader and financial sector veteran with over four decades of experience
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Subscribe To Our Newsletter & Stay Updated
